Summary of FDA Guidance on Patient Preference Information
Written by Arathi Sethumadhavan
This guidance was issued by the FDA last month and provides answers to the following:
What is Patient Preference Information (PPI)?
- Refers to patients’ experiences with a disease or condition and its management
- Can also include the assessments of care partners
- Can be quantitative or qualitative
What will PPI be used for?
- PPI may be used to understand a disease and the impact it has on patients
- PPI may be used to understand the risk-benefit tradeoffs for treatment from the patient’s viewpoint. Specifically, if a large number of well-informed patients believe that the benefits of the product far outweigh the risks, FDA can use this information to influence their decision
- PPI may be used to understand how different sub-groups of the patient population view a product
- PPI will be useful for devices with a direct patient interface, devices with an impact on patient’s quality of life, life-saving devices with a high risk profile, devices developed to treat a rare condition or novel devices
- PPI may be used by the FDA to make decisions related to pre-market applications, humanitarian device exemptions, and de novo requests
- FDA encourages the submission of PPI with sponsors’ device summaries and device labeling to help with their decision-making; however, the submission of PPI is not
What creates a good PPI study?
- A study that involves a representative sample of well-informed patients of adequate size
- A study that captures the heterogeneity of patients
- A study design that effectively communicates benefits, harms, risks, and uncertainties associated with various health outcomes
- A study design that minimizes cognitive biases
- A valid and reliable study with robust data analysis
This guidance will be effective as of October 23, 2016.
How can Core help?
With a team of professionals with strong backgrounds in experimental psychology, statistics, cognition, and behavioral economics, Core has the expertise to conduct well-designed, robust studies that can help you collect the PPI that will help you create a strong, regulatory submission package.